Biaryl compounds as serine protease inhibitors

1. Compound having the structure (I) shown below:

pharmaceutically acceptable salts thereof;

Each E 1 is a 5 to 7 membered saturated or unsaturated carbon ring, bicyclic saturated or unsaturated carbon ring, or 1-8 hydrocarbon chain which may be substituted with one or more hetero groups selected from N, O, S, S(O), and S(O 2 ) which may be saturated or unsaturated; wherein L is pyridine ring

R is —CH═CH—R 2 , —C≡C—R 2 , —C(R 2 )═CH 2 , —C(R 2 )═C(R 3 ), —CH═NR 2 , —C(R 2 )═N—R 3 , 4-7 membered saturated or unsaturated carbon ring system with or without substitution, 4-7 membered saturated or unsaturated hetero ring system with or without substitution, or chain of 2 to 8 carbon atoms having 1 to 5 double or triple bonds with substitutions selected from R 1 , R 2 , or R 3 , these R, R 1 , R 2 , or R 3 do not include —(C 2-4 alkenyl)-CO 2 —C 1-8 alkyl, —(C 2-4 alkenyl)-CO 2 —C 1-8 alkyl-phenyl, and —(C 2-4 alkenyl)-CO 2 —C 1-8 alkyl-O—C 1-4 alkyl;

R 1 is H, —R, —NO 2 , —CN, -halo, —N 3 , —C 1-8 alkyl, —(CH 2 ) n CO 2 R 2 , —C 2-8 alkenyl-CO 2 R 2 , —O(CH 2 ) n CO 2 R 2 , —C(O)NR 2 R 3 , —P(O)(OR 2 ) 2 , alkyl substituted tetrazol-5-yl, —(CH 2 ) n O(CH 2 ) n aryl, —NR 2 R 3 , —(CH 2 ) n OR 2 , —(CH 2 ) n SR 2 , —N(R 2 )C(O)R 3 , —S(O 2 )NR 2 R 3 , —N(R 2 )S(O 2 )R 3 , —(CHR 2 ) n NR 2 R 3 , —C(O)R 3 , (CH 2 ) n N(R 3 )C(O)R 3 , —N(R 2 )CR 2 R 3 substituted or unsubstituted (CH 2 ) n -cycloalkyl, substituted or unsubstituted (CH 2 ) n -phenyl, or substituted or unsubstituted (CH 2 ) n -heterocycle which may be saturated or unsaturated;

m is 1 except that when E 1 is a cyclic ring of more than 5 atoms, then m is 1 or higher, depending upon the size of the ring;

R 2 is H, -halo, -alkyl, -haloalkyl, —(CH 2 ) n -phenyl, —(CH 2 ) 1-3 -biphenyl, —(CH 2 ) 1-4 -Ph-N(SO 2 —C 1-2 -alkyl) 2 , —CO(CHR 1 ) n —OR 1 , —(CHR 1 ) n -heterocycle, —(CHR 1 ) n —NH—CO—R 1 , —(CHR 1 )n-NH—SO 2 R 1 , —(CHR 1 ) n -Ph-N(SO 2 —C 1-2 -alkyl) 2 , —(CHR 1 ) n —C(O)(CHR 1 )—NHR 1 , —(CHR 1 ) n —C(S)(CHR 1 )—NHR 1 , —(CH 2 ) n O(CH 2 ) n CH 3 , —CF 3 , —C 2-5 acyl, —(CHR 1 ) n OH, —(CHR 1 ) n CO 2 R 1 , —(CHR 1 ) n —O-alkyl, —(CHR 1 ) n —O—(CH 2 ) n —O-alkyl, —(CHR 1 ) n —S-alkyl, —(CHR 1 ) n —S(O)-alkyl, —(CHR 1 ) n —S(O 2 )-alkyl, —(CHR 1 ) n —S(O 2 )—NHR 3 , —(CHR 3 ) n —N 3 , —(CHR 3 ) n NHR 4 , 2 to 8 carbon atom alkene chain having 1 to 5 double bonds, 2 to 8 carbon atom alkyne chain having 1 to 5 triple bonds, substituted or unsubstituted-(CHR 3 )n heterocycle, or substituted or unsubstituted-(CHR 3 ) n cycloalkyl which may be saturated or unsaturated;

When n is more than 1, the substitutions R 1 and R 3 may be same or different;

R 3 is H, —OH, —CN, substituted alkyl, —C 2-8 alkenyl, substituted or unsubstituted cycloalkyl, —N(R 1 )R 2 , or 5-6 membered saturated substituted or unsubstituted hetero ring.

—NR 2 R 3 may form a ring system having 4 to 7 atoms or may be bicyclic ring; wherein said ring system may be of carbon or hetero atoms and further it may saturated or unsaturated and also may be substituted or unsubstituted;

W is a direct bond, —CHR 2 —, —CH═CR 2 —, —CR 2 ═CH—, —CR 2 ═CR 2 —, —C≡C—, —O—CHR 2 —, —CHR 2 —O—, —N(R 2 )—C(O)—, —C(O)—N(R 2 )—, —N(R 2 )—CH—(R 3 )—, —CH 2 —N(R 2 )—, —CH(R 1 )—N(R 2 )—, —S—CHR 2 —, —CHR 2 —S—, —S(O 2 )—N(R 2 )—, —C(O)N(R 2 )—(CHR 2 )n-, —C(R 1 R 2 )n-NR 2 —, —N(R 2 )—S(O 2 )—, —R 2 C(O)NR 2 —, —R 2 NC(O)NR 2 —, —CONR 2 CO—, —C(═NR 2 )NR 2 —, —NR 2 C(═NR 2 )NR 2 , —NR 2 O—, —N═NCHR 2 —, or —C(O)NR 2 SO 2 —;

E 2 is 5 to 7 membered saturated or unsaturated carbon ring, 5 to 7 membered saturated or unsaturated hetero ring, bicyclic ring system, C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, alkylaryl, aralkyl, aralkenyl, aralkynyl, alkoxy, alkylthio, or alkylamino;

each X individually is a direct bond, substituted or unsubstituted C 1-4 methylene chain, O, S, NR 2 , S(O), S(O 2 ), or N(O) containing one or two C 1-4 substituted or unsubstituted methylene chains; X at different places may be same or different;

B is H, -halo, —CN, —NH 2 , —(CH 2 ) n —C(═NR 4 )NHR 5 , —(CH 2 ) n —NHR 4 , —(CH 2 ) n NHC(═NR 4 )NR 5 , —(CH 2 ) n —OR 4 , C 1-8 substituted or unsubstituted alkyl, substituted or unsubstituted ring system having 4 to 7 carbon or hetero atoms which may be saturated or unsaturated;

B 1 is selected from B; B 1 and B may be same or different;

There may be more than one similar or different R 2 groups present on E 2 , when E 2 is a cyclic of more than 5 atoms; p is 1 except that when E 2 is a cyclic ring of more than 5 atoms; p is 1 or higher depending upon the size of the ring;

n is 0-4 ;

A is selected from R 1 ;

o is 1 except that when L is a cyclic ring of more than 5 atoms, o is 1 or higher depending upon the size of the ring;

Each V and V 1 individually is selected from R 1 and N-alkyl substituted carboxamidyl (—CONHR) where the alkyl group may be straight, branched, cyclic, or bicyclic; N,N-disubstituted carboxamidyl of the formula —CONR 1 R 2 where R 1 and R 2 may be substituted or unsubstituted alkyl or aryl and may be the same or different; mono- or disubstituted sulfonamides of the formula SO 2 NHR or —SO 2 NR 1 R 2 ; and methylene- or polymethylene chain-extended variants thereof;

Each R 4 and R 5 individually is H, —(CH 2 ) n OH, —C(O)OR 6 , —C(O)SR 6 , —(CH 2 ) n C(O)NR 7 R 8 , —O—C(O)—O—R 7 , an amino acid or a dipeptide;

Each R 6 is H, R 7 , —C(R 7 )(R 8 )—(CH 2 ) n —O—C(O)—R 9 , —(CH 2 ) n —C(R 7 )(R 8 )—O—C(O)R 9 , —(CH 2 ) n —C(R 7 )(R 8 )—O—C(O)—O—R 9 , or —C(R 7 )(R 8 )—(CH 2 ) n —O—C(O)—O—R 9 ; and

Each R 7 , R 8 and R 9 individually is H, alkyl, substituted alkyl, aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, heterocycle, substituted heterocycle, alkylaryl, substituted alkylaryl, cycloalkyl, substituted cycloalkyl, or CH 2 CO 2 alkyl.

2. The compound of claim 1 represented by the structure:

Wherein U is selected from the group consisting of

R 1 is selected from the group consisting of H, OH, OCH 3 , CHO, OSO 2 CF 3 , OCH 2 —CH 2 —OAc, O—CH 2 —CH 2 —OH, OCH 2 CO 2 C 2 H 5 , OCH 2 CO 2 H, CO 2 H, CH 2 OH, OCH(CH 3 ) 2 , OC(O)(CH 3 ) 3 , OCH 2 CONH 2 ,

R 2 is selected from the group consisting of CO 2 -alkyl, CO 2 -aryl, CO 2 -arylalkyl, CO 2 H, CH 2 CO 2 —alkyl, CH 2 OH, CONH 2 ;

R 3 is selected from the group consisting of H, C(O)—NH—R 5 , CO 2 MEM, CO 2 H,

R 4 is selected from the group consisting of C(O)NH—R 6 , —CH(R 7 )—NH—R 6 , CO 2 H, CHO, CO 2 MEM, —CH(R 7 )—O—R 6 , —CH 2 —CH 2 —NH—R 6

R 5 is selected from the group consisting of

R 6 is selected from the group consisting of

R 7 is selected from the group consisting of H, CH 3 , —(CH 2 ) n —CO 2 H, —(CH 2 ) n —CO 2 -alkyl wherein n=0-3;

R 8 selected from the group consisting of —CH 2 —CCl 3 , —CH 3 , C 2 H 5 , CH 2 C 6 H 5 , C(CH 3 ) 3 ,

 and X is N;

and pharmaceutically acceptable salts thereof; and prodrug thereof.

3. The compound of claim 1 represented by the structure:

Wherein R is selected from the group consisting of

R 1 is selected from the group consisting of H, OH OCH 3 , CHO, OSO 2 CF 3 , OCH 2 —CH 2 —OAc, O—CH 2 —CH 2 —OH, OCH 2 CO 2 C 2 H 5 , OCH 2 CO 2 H, CO 2 H, CH 2 OH, OCH(CH 3 ) 2 , OC(O)(CH 3 ) 3 , OCH 2 CONH 2 ,

R 2 is selected from the group consisting of CO 2 -alkyl, CO 2 -aryl, CO 2 -arylalkyl, CO 2 H, CH 2 CO 2 -alkyl, CH 2 OH, CONH 2 ;

R 3 is selected from the group consenting of H, C(O)—NH—R 5 , CO 2 MEM, CO 2 H,

R 4 is selected from the group consisting of C(O)NH—R 6 , —CH(R 7 )—NH—R 6 , CO 2 H, CHO, CO 2 MEM, —CH(R 7 )—O—R 6 , —CH 2 —CH 2 NH—R 6

R 5 is selected from the group consisting of

R 6 is selected from the group consisting of

R 7 is selected from the group consisting of H, CH 3 , —(CH 2 ) n —CO 2 H, —(CH 2 ) n —CO 2 -alkyl wherein n=0-3;

R 8 is selected from the group consisting of —CH 2 —CCl 3 , —CH 3 , C 2 H 5 , CH 2 C 6 H 5 , C(CH 3 ) 3 ,

 and X is N;

and pharmaceutically acceptable salts thereof; and prodrug thereof.

4. The compound of claim 1 represented by the structure:

Wherein R is selected from the group consisting of

R 1 is selected from the group consisting of H, OH, OCH 3 , CHO, OSO 2 CF 3 , OCH 2 —CH 2 —OAc, O—CH 2 —CH 2 —OH, OCH 2 CO 2 C 2 H 5 , OCH 2 CO 2 H, CO 2 H, CH 2 OH, OCH(CH 3 ) 2 , OC(O)(CH 3 ) 3 , OCH 2 CONH 2 ,

R 2 is selected from the group consisting of CO 2 -alkyl, CO 2 -aryl, CO 2 -arylalkyl, CO 2 H, CH 2 CO 2 -alkyl, CH 2 OH, CONH 2 ;

R 3 is selected from the group consenting of H, C(O)—NH—R 5 , CO 2 MEM, CO 2 H,

R 4 is selected from the group consisting of C(O)NH—R 6 , —CH(R 7 )—NH—R 6 , CO 2 H, CHO, CO 2 MEM, —CH(R 7 )—O—R 6 , —CH 2 —CH 2 —NH—R 6

R 5 is selected from the group consisting of

R 6 is selected from the group consisting of

R 7 is selected from the group consisting of H, CH 3 , —(CH 2 ) n —CO 2 H, —(CH 2 ) n —CO 2 -alkyl wherein n=0-3;

R 8 is selected from the group consisting of —CH 2 —CCl 3 , —CH 3 , C 2 H 5 , CH 2 C 6 H 5 , C(CH 3 ) 3 ,

 and X is N;

and pharmaceutically acceptable salts thereof; and prodrug thereof.

5. A pharmaceutical composition containing at least one compound according to claim 1 .

6. A method for inhibiting the coagulation cascade and preventing or limiting coagulation by administering to a patient an effective amount of at least one compound according to claim 1 .

7. A method for inhibiting the formation of emboli or thromboli in blood vessels by administering to a patient an effective amount of at least one compound according to claim 1 .

8. A method for treating at least one condition selected from the group consisting of thrombolymphangitis thrombosinusitis, thromboendocarditis, thromboangitis, unstable angina, and thromboarteritis which comprises administering to a patient an effective amount of at least one compound according to claim 1 .

9. A method for inhibiting thrombus formation following angioplasty which comprises administering to a patient an effective amount of at least one compound according to claim 1 .

10. A method for preventing arteria occlusion following thrombolytic therapy which comprises administering to a patient an effective amount of at least one compound according to claim 1 and an effective amount of at least another antithrombolytic agent.

11. The method of claim 10 wherein said other antithrombolytic agent is selected from the group consisting of tissue plasminogen activators, streptokinase and urokinase, and functional derivatives thereof.

12. A method of claim 6 which further comprises administering a further anticoagulant agent to said patient.

13. The method of claim 12 wherein said further anticoagulant agent is selected from the group consisting of heparin, aspirin, and warfarin.

14. A method for treating a patient in need of an anti-inflammatory agent which comprises administering to said patient an effective amount of at least one of the compounds according to claim 1 .

15. A method for inhibiting in vitro clotting of blood which comprises contacting said blood with at least one compound according to claim 1 .

16. The method of claim 15 which comprises inhibiting said blood in tubes.

17. The compound of claim 1 represented by the structure;

wherein R═CH═CH 2 ; R 1 ═H; R 2 ═CO 2 H; R 3 ═C(O)NHCH 2 CH(CH 3 ) 2 ; X═N and R 4 ═

pharmaceutically acceptable salts thereof and prodrugs thereof.

18. The compound of claim 3 wherein R═CH═CH 2 ; R 1 ═OCH 3 ; R 2 ═CO 2 H; R 3 ═C(O)NHR 5 ; R 5 ═CH 2 Cyclopropyl; R 4 ═C(O)NHR 6 and

pharmaceutically acceptable salts thereof and prodrugs thereof.